The solution combines three medications delivering the broadest spectrum of protection against internal and…
Tag:
Boehringer Ingelheim
-
-
Lifestyle & Healthslider
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
by Karine Ayoubby Karine AyoubIngelheim, Germany, Mon, 16/09/2024 – 12:00 Boehringer Ingelheim announced today that the FIBRONEER™-IPF trial…
-
Lifestyle & Healthslider
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
by Karine Ayoubby Karine AyoubR&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)…
-
Lifestyle & Healthslider
Boehringer Ingelheim Breaks Guinness World Records™ title In Solidarity with Rare Disease Patients Around the World
by Karine Ayoubby Karine AyoubTo mark the Rare Disease Awareness Month, Boehringer Ingelheim created the Largest Video Chain…
-
Lifestyle & Healthslider
Boehringer Ingelheim Launches Advanced Educational Program on Heart Failure to Empower Multidisciplinary Healthcare Professionals
by Karine Ayoubby Karine AyoubHeart failure is a progressive and potentially fatal condition that affects over 60 million…
-
Lifestyle & Healthslider
Boehringer Ingelheim increases commitments to sustainable development, to impact 50 million people through social innovation
by Karine Ayoubby Karine AyoubBoehringer Ingelheim marks One Health Day 2021 by evolving commitments to sustainable development relating…
-
Lifestyle & Healthslider
Boehringer Ingelheim shares updated 2030 environmental sustainability commitments
by Karine Ayoubby Karine AyoubBoehringer Ingelheim marks COP26 by announcing updates to its strategic approach to sustainable development…
-
Lifestyle & Healthslider
Boehringer Ingelheim increases commitments to sustainable development, investing in health innovation and collaborations to expand access and improve healthcare for 50 million people in vulnerable communities by 2030
by Karine Ayoubby Karine Ayoub• Boehringer Ingelheim marks the World Health Summit 2021 by announcing updates to its…
-
Lifestyle & Healthslider
Landmark trial, EMPEROR-Preserved, demonstrates empagliflozin is the first therapy to show statistically significant improvement in heart failure outcomes in adults with preserved ejection fraction
by Karine Ayoubby Karine AyoubIn this clinical study for adults with heart failure with preserved ejection fraction, empagliflozin…
-
Lifestyle & Healthslider
Leading Healthcare Experts Highlight Importance of Multidisciplinary Treatment Approach at ‘2021 Regional Interchange on Diabetes’
by Karine Ayoubby Karine AyoubOver 300 nephrologists, endocrinologists, internists, diabetologists and cardiologists from across the Middle East and…
Newer Posts